Cerebral Dopamine Neurotrophic Factor

📖 Wiki Page

protein1504 wordssynced 2026-04-02

Cerebral Dopamine Neurotrophic Factor

Introduction

Cerebral Dopamine Neurotrophic Factor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

--- [@lindholm2007]
title: Cerebral Dopamine Neurotrophic Factor [@voutilainen2009]
description: Neurotrophic factor protecting dopaminergic [neurons](/entities/neurons). Being developed for PD therapy. [@airavaara2012]
--- [@shen2021]

<div class="infobox infobox-protein"> [@mtlik2018]
<table>
<tr><th colspan="2" class="infobox-header">Cerebral Dopamine Neurotrophic Factor</th></tr>
<tr><td class="label">Protein Name</td><td>Cerebral Dopamine Neurotrophic Factor (CDNF)</td></tr>
<tr><td class="label">Gene</td><td><a href="/genes/CDNF">CDNF</a></td></tr>
<tr><td class="label">UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/Q96GS4">Q96GS4</a></td></tr>
<tr><td class="label">PDB ID</td><td>2NBM</td></tr>
<tr><td class="label">Molecular Weight</td><td>~18 kDa (160 amino acids)</td></tr>
<tr><td class="label">Subcellular Localization</td><td>Secreted, endoplasmic reticulum</td></tr>
<tr><td class="label">Protein Family</td><td>CDNF, ARMET/MANF family-like proteins</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

...

Cerebral Dopamine Neurotrophic Factor

Introduction

Overview

Cerebral Dopamine Neurotrophic Factor (CDNF) is a secreted neurotrophic factor that belongs to the conserved ARMET (Armadillo Repeat Protein Inferred from Tetrahymena) family. CDNF is primarily known for its potent protective and regenerative effects on dopaminergic neurons, making it a promising therapeutic candidate for [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative disorders affecting the dopaminergic system.

CDNF was discovered in 2003 as a novel neurotrophic factor with specific activity toward dopaminergic neurons. Unlike classical neurotrophins such as [BDNF](/proteins/bdnf) or [GDNF](/proteins/gdnf), CDNF has a unique mechanism of action and structural features that make it particularly effective at protecting neurons from various insults.

Structure

CDNF possesses a distinctive structure characterized by:

N-terminal signal peptide: Directs secretion via the classical secretory pathway
Armadillo-repeat domain: Forms a superhelical structure involved in protein-protein interactions
C-terminal domain: Contains a conserved MANF-like fold with a metal-binding motif
disulfide bonds: Three conserved cysteine residues form stabilizing disulfide bridges

The three-dimensional structure of CDNF (PDB: 2NBM) reveals a unique fold that distinguishes it from other neurotrophic factors. The protein forms a dimer in solution, which may be relevant to its biological activity.

Function

CDNF exerts multiple protective functions in the nervous system:

Dopaminergic Neuron Protection

CDNF is the most potent known neurotrophic factor for dopaminergic neurons in the substantia nigra pars compacta. It promotes:

Survival of dopaminergic neurons
Protection against 6-hydroxydopamine (6-OHDA) toxicity
Protection against MPTP-induced parkinsonism
Restoration of dopaminergic function in animal models

Protein Folding and ER Stress

CDNF localizes to the endoplasmic reticulum (ER) where it:

Functions as an ER stress response protein
Helps maintain ER homeostasis
Reduces accumulation of misfolded proteins
Activates the unfolded protein response (UPR) pathways

Anti-inflammatory Effects

CDNF exhibits anti-inflammatory properties by:

Reducing microglial activation
Decreasing pro-inflammatory cytokine production
Modulating neuroinflammation in models of neurodegeneration

Neurotrophic Activity

Beyond dopaminergic neurons, CDNF also affects:

Motor neurons
Sensory neurons
Hippocampal neurons
Cortical neurons

Mechanism of Action

CDNF signals through multiple pathways to exert its neuroprotective effects:

Receptor-mediated Signaling

While the precise receptor for CDNF is still being characterized, evidence suggests it may interact with:

GRP78/BiP: A major ER chaperone that also serves as a cell surface receptor for CDNF
[RAGE](/entities/rage-receptor): Receptor for Advanced Glycation End products
Unknown CNS-specific receptor: Ongoing research aims to identify the primary neuronal receptor

Intracellular Signaling Pathways

CDNF activates several key signaling cascades:

PI3K/Akt pathway: Promotes cell survival and inhibits [apoptosis](/entities/apoptosis)
MAPK/ERK pathway: Supports neuronal differentiation and survival
JAK/STAT pathway: Involved in transcriptional regulation of pro-survival genes
Nrf2 pathway: Activates antioxidant response elements

ER Stress Mitigation

CDNF directly modulates ER stress pathways:

Upregulates ER chaperones (BiP, GRP94)
Reduces CHOP expression
Restores calcium homeostasis
Inhibits caspase activation

Role in Neurodegenerative Diseases

Parkinson's Disease

CDNF is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis and therapy:

Neuronal protection: CDNF protects substantia nigra dopaminergic neurons from degeneration
Alpha-synuclein mitigation: May reduce [alpha-synuclein](/proteins/alpha-synuclein) aggregation
Mitochondrial protection: Helps maintain mitochondrial function
Clinical trials: CDNF is being developed as a disease-modifying therapy for PD

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease):

CDNF may protect cholinergic neurons
ER stress reduction could benefit neuronal function
Anti-inflammatory effects may slow disease progression

Amyotrophic Lateral Sclerosis

CDNF shows promise in [ALS](/diseases/amyotrophic-lateral-sclerosis):

Protects motor neurons
Reduces ER stress in motor neurons
May improve survival in animal models

Other Neurodegenerative Disorders

Multiple System Atrophy: Neuroprotective effects on autonomic neurons
Dementia with Lewy Bodies: May protect dopaminergic and cortical neurons
Huntington's Disease: Potential benefits through ER stress modulation

Therapeutic Implications

CDNF represents one of the most promising neurotrophic factors for neurodegenerative disease therapy:

Clinical Development

Clinical trials: CDNF has reached clinical trials for Parkinson's disease
Delivery methods: Research on intranasal, intraventricular, and AAV-mediated delivery
Combination therapy: Being explored with other neurotrophic factors

Advantages over GDNF

CDNF offers several advantages:

Better solubility and stability
More potent neuroprotective effects
Works through distinct mechanisms
May be more effective in chronic disease models

Challenges

Delivery to the central nervous system
Optimal dosing regimens
Long-term safety profile
Patient selection criteria

Interactions and Network

CDNF interacts with multiple proteins and pathways:

GRP78/BiP: ER chaperone and potential receptor
[PINK1](/proteins/pink1-protein): Parkin-independent mitophagy pathway
[Parkin](/proteins/parkin-protein): E3 ubiquitin ligase affected in familial PD
[DJ-1](/proteins/dj1-park7): Parkinson's disease protein involved in oxidative stress
[UPR](/entities/unfolded-protein-response) pathway components: IRE1, PERK, ATF6
[BDNF](/proteins/bdnf): Other neurotrophic factor

Molecular Mechanisms

ER Stress Response

CDNF mitigates ER stress through the unfolded protein response (UPR):

Mermaid diagram (expand to render)

Signaling Cascades

CDNF activates multiple pro-survival pathways:

| Pathway | Effect | Neuronal Outcome |
|---------|--------|------------------|
| PI3K/Akt | Cell survival signaling | Reduced apoptosis |
| MAPK/ERK | Differentiation, survival | Neuroprotection |
| JAK/STAT | Gene transcription | Pro-survival genes |
| Nrf2 | Antioxidant response | ROS detoxification |

Mitochondrial Protection

CDNF protects mitochondria through:

Maintaining mitochondrial membrane potential
Reducing cytochrome c release
Enhancing mitophagy (with PINK1/Parkin)
Improving ATP production

Clinical Development

Clinical Trials

CDNF has reached clinical trials for Parkinson's disease:

| Trial Phase | Status | Notes |
|-------------|--------|-------|
| Phase I | Completed | Safety in PD patients |
| Phase II | Ongoing | Efficacy assessment |
| Combination trials | Planning | With standard PD medications |

Delivery Methods

Multiple delivery approaches are being explored:

| Method | Advantages | Challenges |
|--------|------------|------------|
| AAV-CDNF | Long-term expression | CNS delivery |
| Intranasal | Non-invasive | Limited diffusion |
| Intrathecal | Direct CNS access | Invasive |
| Protein infusion | Direct delivery | BBB penetration |

Research Directions

Current research focuses on:

Receptor identification: Determining the primary neuronal receptor for CDNF

Mechanism elucidation: Understanding downstream signaling in detail

Clinical efficacy: Completing clinical trials for Parkinson's disease

Combination approaches: Developing CDNF-based combination therapies

Biomarkers: Identifying biomarkers for treatment response

Comparison with GDNF

CDNF has several advantages over GDNF:

| Feature | CDNF | GDNF |
|---------|------|------|
| Structure | Unique fold | GDNF family |
| Mechanism | ER stress mitigation | Ret-dependent |
| Solubility | Better | Limited |
| Distribution | Broader | More restricted |
| Safety profile | Favorable | Requires careful dosing |

External Links

[UniProt Q96GS4](https://www.uniprot.org/uniprot/Q96GS4)
[PDB 2NBM](https://www.rcsb.org/structure/2NBM)
[CDNF Clinical Trials](https://clinicaltrials.gov/search?term=CDNF)

Background

The study of Cerebral Dopamine Neurotrophic Factor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Petäistö et al., CDNF: Structure and function of a novel neurotrophic factor (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18627039/)

[Lindholm et al., Novel neurotrophic factor CDNF protects dopaminergic neurons (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17482818/)

[Voutilainen et al., CDNF attenuates endoplasmic reticulum stress in Parkinson's disease models (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19720051/)

[Airavaara et al., CDNF gene therapy protects dopaminergic neurons (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22252227/)

[Shen et al., CDNF: A promising therapeutic agent for neurodegenerative disorders (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34058427/)

[Mätlik et al., AAV-CDNF gene therapy for Parkinson's disease (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30012408/)

[Petäistö et al., CDNF: Structure and function of a novel neurotrophic factor (2008)](https://pubmed.ncbi.nlm.nih.gov/18627039/)

[Lindholm et al., Novel neurotrophic factor CDNF protects dopaminergic neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/17482818/)

[Voutilainen et al., CDNF attenuates endoplasmic reticulum stress in Parkinson's disease models (2009)](https://pubmed.ncbi.nlm.nih.gov/19720051/)

[Airavaara et al., CDNF gene therapy protects dopaminergic neurons (2012)](https://pubmed.ncbi.nlm.nih.gov/22252227/)

[Shen et al., CDNF: A promising therapeutic agent for neurodegenerative disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/34058427/)

[Mätlik et al., AAV-CDNF gene therapy for Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30012408/)

[Timmer M, et al., (2017). CDNF: The promising neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry.](https://pubmed.ncbi.nlm.nih.gov/28088420/)

[Ar挂钩 N, et al., (2019). CDNF and MANF in ER stress response. Mol Cell Neurosci.](https://pubmed.ncbi.nlm.nih.gov/30826568/)

📖 View canonical wiki page →

Cerebral Dopamine Neurotrophic Factor

Cerebral Dopamine Neurotrophic Factor

Introduction

Overview

Cerebral Dopamine Neurotrophic Factor

Introduction

Overview

Structure

Function

Dopaminergic Neuron Protection

Protein Folding and ER Stress

Anti-inflammatory Effects

Neurotrophic Activity

Mechanism of Action

Receptor-mediated Signaling

Intracellular Signaling Pathways

ER Stress Mitigation

Role in Neurodegenerative Diseases

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Disorders

Therapeutic Implications

Clinical Development

Advantages over GDNF

Challenges

Interactions and Network

Molecular Mechanisms

ER Stress Response

Signaling Cascades

Mitochondrial Protection

Clinical Development

Clinical Trials

Delivery Methods

Research Directions

Comparison with GDNF

See Also

External Links

Background

References